Analyst Insights: Genomic Health, Linkedin, JPMorgan, KBW, Rovi May 22nd
Linkedin Corporation (NYSE:LNKD): Piper Jaffray believes the recent pullback in shares of LinkedIn presents an attractive entry point and reiterates an Overweight rating on the stock with a $145 price target. Piper thinks LinkedIn is seeing significant iPad app penetration, which it believes will drive greater levels of member engagement.
Genomic Health Inc. (NASDAQ:GHDX): After conducting due diligence with oncology surgeons, JMP Securities believes that Genomic’s DCIS test could potentially generate a large amount of revenue. The firm reiterates an Outperform rating.
JPMorgan Chase & Co. (NYSE:JPM): UBS reduced JPMorgan estimates citing the suspension of the stock buyback program but said valuation remains compelling. Shares are Buy rated.
KBW Inc (NYSE:KBW): After viewing a presentation by KBW’s management, JMP Securities identifies the company as its favorite idea from the firm’s recent conference. The firm reiterates a $23 target and Outperform rating on the stock.
Rovi Corporation (NASDAQ:ROVI): After meeting with ROVI’s management, JMP Securities reports that it’s as upbeat about the company’s prospects as ever, despite recent changes in its management. The firm expects the company to generate mid-to high teens CAGR earnings growth over the next two years and reiterates an Outperform rating.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.